The all-in-one platform to find and track your investmentsDiscover the features
ISIN : US7170811035
|1 year return||
|5 years return||
For this company, we show you a quick help in graphical form that tells you if the stock looks overvalued, undervalued or fairly priced, and by how much. Stop paying too much for your shares.
Unlock valuation chart for this company
30 years +
4x / year
|Price to Book||Payout ratio||PE Ratio||PEG Ratio|
|2.84||26 %||8.62 x||1.17|
|Price to Sales||Price / FCF||Enterprise Value Revenue|
Biohaven Pharmaceuticals BHVN recently announced that the phase II/III HEALY ALS platform study evaluating verdiperstat for treating Amyotrophic Lateral Sclerosis (ALS) failed.
ALS is a progressive, rare and life-threatening neuromuscular disease cha
(Adds background and details of when shots were authorized)
Sept 29 (Reuters) - Around 3.2 million people in the United States received updated COVID-19 booster shots over the past week, the Centers for Disease Control and Prevention said on Thursday
Biohaven Pharmaceutical Holding Company Ltd (NASDAQ: BHVN) announced results from a focused analysis of verdiperstat in the HEALEY ALS Platform Trial in amyotrophic lateral sclerosis (ALS).
Verdiperstat did not statistically differentiate from placebo
Moderna MRNA announced that the European Medicines Agency accepted its conditional marketing authorization (CMA) application seeking approval to use a 50-µg booster dose of its bivalent BA.4/BA.5 Omicron-targeting COVID-19 vaccine, mRNA-1273.222, in i
PFE and its partner BioNTech BNTX have submitted a variation to the marketing authorization (MA), which seeks to expand the label of their bivalent BA.4/BA.5 Omicron-targeting COVID-19 vaccine for use in children aged five through 11 year
Sept 29 (Reuters) - Biohaven Pharmaceutical Holding Company Ltd said on Thursday its experimental drug to treat amyotrophic lateral sclerosis (ALS) failed a clinical study, the second therapy by the drugmaker to fail trials in recen
Merck & Co Inc (NYSE: MRK) signed a cooperation framework agreement in China for its COVID-19 antiviral pills, which were co-developed by Ridgeback Therapeutics.
The pharma giant has granted Sinopharm exclusive import and distribution rights to Lagevr
When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") above 14x, you may consider Pfizer Inc.
(NYSE:PFE) as an attractive investment with its 8.5x P/E ratio.
However, the P/E might be low for a reason and it
One of the country's top vaccine experts has stirred debate in recent weeks by suggesting that not everyone should get the latest COVID-19 vaccine boosters and that the CDC is "overselling" the new shot.
Paul Offit, director of the Vaccine Educat
Pfizer (PFE) is one of the stocks most watched by Zacks.com visitors lately.
So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.
Over the past month, shares of this drugmaker have return
Biogen stock (BIIB) is booming amid as Wall Street speculates about a potential profit boom after a promising study detailed the company's new Alzheimer's drug in partnership with Japan’s Eisai.
"We think that lecanemab holds mega blockbuster potenti
Experts are concerned that the US isn’t doing enough to support the development of the next wave of vaccines and treatments that the world needs to fight the Covid-19 pandemic
Add this stock and others to your own virtual portfolio and get personalised information : total annual dividends & total value, sectors breakdown, etc.